MagForce AG Installs NanoActivator(r) at the Kiel University Hospital
Berlin, Germany, Dec. 19, 2013 (GLOBE NEWSWIRE) -- MagForce AG (Frankfurt,
Xetra:MF6), a medical technology company that focuses on the field of oncology
and is a leader in the nanotechnology sector, today announced the installation
of the third NanoActivator^®. The NanoActivator^® was installed as part of the
preparations for the new glioblastoma study at the Kiel University Hospital.
About MagForce AG
MagForce AG is a leading medical device company in the field of nanomedicine
in oncology, listed in the entry standard (MF6). The Company's proprietary,
NanoTherm^® therapy, enables the targeted treatment of solid tumors through
the intratumoral generation of heat via activation of superparamagnetic
nanoparticles. NanoTherm^®, NanoPlan^®, and NanoActivator^® are components of
the therapy and have received EU-wide regulatory approval as medical devices
for the treatment of brain tumors. MagForce, NanoTherm^®, NanoPlan^®, and
NanoActivator^® are trademarks of MagForce AG in selected countries. For more
information, please visit www.magforce.com.
This release may contain forward-looking statements and information which may
be identified by formulations using terms such as "expects", "aims",
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will".
Such forward-looking statements are based on our current expectations and
certain assumptions, which may be subject to a variety of risks and
uncertainties. The results actually achieved by MagForce AG may substantially
differ from these forward-looking statements. MagForce AG assumes no
obligation to update these forward-looking statements or to correct them in
case of developments, which differ from those, anticipated.
For further information:
MC Services AG
T +49 211 529252 22
F +49 211 529252 29
M +49 151 12 555 759
MagForce_Press Release_December 19, 2013
Press spacebar to pause and continue. Press esc to stop.